{"id":38077,"date":"2026-05-14T15:21:08","date_gmt":"2026-05-14T09:36:08","guid":{"rendered":"https:\/\/www.revoscience.com\/en\/?p=38077"},"modified":"2026-05-14T16:13:39","modified_gmt":"2026-05-14T10:28:39","slug":"clinical-trials-enter-digital-era-as-researchers-highlight-virtual-simulations","status":"publish","type":"post","link":"https:\/\/www.revoscience.com\/en\/clinical-trials-enter-digital-era-as-researchers-highlight-virtual-simulations\/","title":{"rendered":"Clinical Trials Enter Digital Era as Researchers Highlight Virtual Simulations"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

BARCELONA, March 23 \u2014 Clinical trials, the backbone of modern medicine, may be entering a new digital era. <\/p>\n\n\n\n

A review published in Reviews<\/a> on Recent Clinical Trials by Francisco Epelde, Dolores Rexachs, \u00c1lvaro Wong, and Emilio Luque examines the growing role of Virtual Clinical Trials (VCTs). These computer-based simulations test drugs and therapies without enrolling human patients.<\/p>\n\n\n\n

Digital simulations<\/h3>\n\n\n\n

The study, conducted by researchers at Parc Taul\u00ed Hospital Universitari and the Universitat Aut\u00f2noma de Barcelona, highlights how VCTs use mathematical models, artificial intelligence, and large datasets to create \u201cvirtual populations.\u201d <\/p>\n\n\n\n

These digital patients can represent different ages, genetic traits, and disease profiles, allowing researchers to explore scenarios that would be costly or ethically difficult in traditional trials.<\/p>\n\n\n\n

Speed and cost<\/h3>\n\n\n\n

Traditional trials often cost hundreds of millions of dollars and take years to complete. Virtual trials, by contrast, can deliver results in days. <\/p>\n\n\n\n

The authors say this speed could prove critical during pandemics or fast-moving health crises, where rapid decisions save lives. Simulations also allow researchers to identify weak drug candidates earlier, reducing risks to human participants.<\/p>\n\n\n\n

Ethical concerns<\/h3>\n\n\n\n

The paper warns that VCTs are not a replacement for human studies. Models depend on the quality of underlying data and may miss rare side effects or oversimplify patient responses. <\/p>\n\n\n\n

\u201cVirtual trials must be validated against real-world evidence,\u201d the authors note, stressing that patient experiences and quality-of-life outcomes cannot be replicated by algorithms alone.<\/p>\n\n\n\n

Equity and bias<\/h3>\n\n\n\n

Advocates say VCTs could broaden representation by including groups often underrepresented in clinical research. <\/p>\n\n\n\n

However, the review cautions that biased or incomplete datasets risk reproducing inequalities inside simulations. Ensuring diversity requires transparent assumptions and ongoing auditing.<\/p>\n\n\n\n

Regulation<\/h3>\n\n\n\n

Existing regulatory frameworks were designed for human-based trials and do not easily apply to digital simulations. <\/p>\n\n\n\n

The authors call for updated standards that prioritize transparency, validation, and safeguards to trigger human testing when uncertainty is high. Ethical review boards, they argue, must adapt to evaluate algorithms as well as protocols.<\/p>\n\n\n\n

Hybrid future<\/h3>\n\n\n\n

The review concludes that the future of clinical research will be hybrid, combining virtual trials, digital twins, synthetic control arms, and traditional studies. Used responsibly, VCTs could accelerate drug development and reduce risks. Used carelessly, they could amplify bias and erode trust.<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

BARCELONA, March 23 \u2014 Clinical trials, the backbone of modern medicine, may be entering a new digital era. <\/p>\n","protected":false},"author":2,"featured_media":38078,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14,17],"tags":[],"class_list":["post-38077","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-innovation","category-research"],"featured_image_urls":{"full":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era-.webp",768,576,false],"thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era--200x200.webp",200,200,true],"medium":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era--675x506.webp",675,506,true],"medium_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era-.webp",750,563,false],"large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era-.webp",750,563,false],"1536x1536":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era-.webp",768,576,false],"2048x2048":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era-.webp",768,576,false],"ultp_layout_landscape_large":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era-.webp",768,576,false],"ultp_layout_landscape":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era--768x570.webp",768,570,true],"ultp_layout_portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era--600x576.webp",600,576,true],"ultp_layout_square":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era--600x576.webp",600,576,true],"newspaper-x-single-post":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era--760x490.webp",760,490,true],"newspaper-x-recent-post-big":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era--550x360.webp",550,360,true],"newspaper-x-recent-post-list-image":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era--95x65.webp",95,65,true],"web-stories-poster-portrait":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era--640x576.webp",640,576,true],"web-stories-publisher-logo":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era--96x96.webp",96,96,true],"web-stories-thumbnail":["https:\/\/www.revoscience.com\/en\/wp-content\/uploads\/2026\/05\/Clinical-Trials-Enter-Digital-Era--150x113.webp",150,113,true]},"author_info":{"info":["RevoScience"]},"category_info":"Innovation<\/a> Research<\/a>","tag_info":"Research","comment_count":"0","_links":{"self":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/38077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/comments?post=38077"}],"version-history":[{"count":2,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/38077\/revisions"}],"predecessor-version":[{"id":38080,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/posts\/38077\/revisions\/38080"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media\/38078"}],"wp:attachment":[{"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/media?parent=38077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/categories?post=38077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.revoscience.com\/en\/wp-json\/wp\/v2\/tags?post=38077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}